Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...
Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than ...
1don MSN
Recursion eyes breakthrough with REC-4881 drug for rare genetic condition, but shares pull back
Earlier this year, Recursion Pharmaceuticals Inc RXRX initiated discussions with the FDA for the design of a registrational ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best AI stocks under $50 to buy right now. On May 6, Recursion ...
1don MSN
Recursion outlines runway into early 2028 while maintaining 2026 cash operating expenses under $390M
Q1 2026 Management View "Since stepping into this role, I've been focused on a singular question: how do we harness the full power of AI to consistently and with urgency create better medicines for ...
SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Wednesday reported a loss of $117.5 million in its first quarter. The Salt Lake City-based company said it had a ...
On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results